Who
Franz B. Humer
Director
Company insider
Files Form 4 as: Director, Allogene Therapeutics; Director, Citigroup; Director, Kite Pharma.
In numbers
- Trades disclosed
- 83
- Buys
- 1
- Sells
- 2
- Bought
- $540K
- Sold
- $46K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 1 Jul 2012
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 5 Dec 2024filed 9 Dec 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K9,221 at $2.16 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,541 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —61,475 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $26K11,200 at $2.34 | filing |
| 13 Jun 2023filed 15 Jun 2023 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —74,561 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,178 at $0.00 | filing |
| 10 Jun 2021filed 11 Jun 2021 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,498 at $0.00 | filing |
| 5 Jun 2020filed 9 Jun 2020 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —9,969 at $0.00 | filing |
| 6 Jun 2019filed 24 Jun 2019 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,377 at $0.00 | filing |
| 1 Apr 2019filed 2 Apr 2019 | C CitigroupMoney-centre banks | SEC FORM 4 Code A | $9,543151.35 at $63.05 | filing |
| 1 Apr 2019filed 2 Apr 2019 | C CitigroupMoney-centre banks | SEC FORM 4 Code A | $92614.69 at $63.05 | filing |
| 14 Feb 2019filed 15 Feb 2019 | C CitigroupMoney-centre banks | SEC FORM 4 Code A | —600.69 at $0.00 | filing |
| 2 Jan 2019filed 4 Jan 2019 | C CitigroupMoney-centre banks | SEC FORM 4 Code A | $8,287142.85 at $58.01 | filing |
| 2 Jan 2019filed 4 Jan 2019 | C CitigroupMoney-centre banks | SEC FORM 4 Code A | $2,10136.21 at $58.01 | filing |
| 15 Oct 2018filed 17 Oct 2018 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Bought | $540K30,000 at $18.00 | filing |
| 15 Oct 2018filed 17 Oct 2018 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code C | —74,870 | filing |
| 15 Oct 2018filed 17 Oct 2018 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —14,261 at $0.00 | filing |
News
Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026Head to Head Comparison: Generate Biomedicines (NASDAQ:GENB) vs. Allogene Therapeutics (NASDAQ:ALLO)ALLO · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Franz B. Humer; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.